Long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ
Improved imaging, surgical techniques, and pathologic evaluation likely have decreased local recurrence rates for patients with ductal carcinoma in situ (DCIS). We present long-term outcomes of a large single-institution series after breast-conserving surgery (BCS) and adjuvant radiation therapy (RT).
We retrospectively reviewed the records of 245 women treated for DCIS with BCS and RT between 2001 and 2007. Competing risk analysis was used to calculate local recurrence (LR) as a first event with the development of a second non-breast malignancy, contralateral breast cancer, and death as competing first events.
At a median follow-up of 10.6 years, 4 patients had a LR (2 DCIS, 2 invasive) as a first event with a cumulative LR incidence of 0.0% and 1.5% at 5 and 10 years, respectively. Most patients had > 2 mm margins (90%), specimen radiographs (93%), and received a tumor bed boost (99%). The majority (60%) of patients with hormone receptor-positive disease received adjuvant endocrine therapy. Ten-year cumulative incidence of contralateral breast cancer (CBC) was 7.9%, second non-breast malignancy was 4.5%, and death unrelated to breast cancer was 3.5%. Family history, age at diagnosis, and receipt of endocrine therapy were not significantly associated with the development of CBC (all P > 0.05).
With mature follow-up, our rates of local recurrence following breast-conserving therapy for DCIS remain very low (1.5% at 10 years). The incidence of CBC was higher than the LR incidence. Predisposing factors for the development of CBC are worthy of investigation.
KeywordsBreast cancer Ductal carcinoma in situ Outcomes Breast-conserving therapy Radiation therapy
There was no specific funding supporting this research.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The DF/HCC institutional review board approved this study and waived the requirement for informed consent.
- 4.Hiramatsu H, Bornstein BA, Recht A et al (1995) Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am 1:55–61Google Scholar
- 6.Morrow M, Van Zee KJ, Solin LJ et al (2016) Society of surgical oncology-American Society for radiation oncology-American Society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. https://doi.org/10.1200/JCO.2016.68.3573 Google Scholar
- 8.Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European organization for research and treatment of cancer trial 10853. J Clin Oncol 19:2263–2271. https://doi.org/10.1200/jco.2001.19.8.2263 CrossRefGoogle Scholar
- 9.Fisher ER, Costantino J, Fisher B et al (1995) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer 75:1310–1319CrossRefGoogle Scholar
- 16.Margolese R, Cecchini RS, Julian TB et al (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849–856. https://doi.org/10.1016/S0140-6736(15)01168-X.Primary CrossRefGoogle Scholar
- 18.Donker M, Litière S, Werutsky G et al (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31:4054–4059. https://doi.org/10.1200/JCO.2013.49.5077 CrossRefGoogle Scholar
- 20.Kong I, Narod SA, Taylor C et al (2014) Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 21:e96–e104. https://doi.org/10.3747/co.21.1604 CrossRefGoogle Scholar
- 22.Lester SC, Bose S, Chen Y et al (2009) Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 133:15–25Google Scholar
- 28.Forbes JF, Sestak I, Howell A et al (2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 387:866–873. https://doi.org/10.1016/S0140-6736(15)01129-0 CrossRefGoogle Scholar